BidaskClub cut shares of Ardelyx (NASDAQ:ARDX) from a hold rating to a sell rating in a research note released on Wednesday morning.
Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Ardelyx from a buy rating to a hold rating in a report on Friday, February 2nd. Wedbush restated an outperform rating and set a $12.00 price target (down from $13.00) on shares of Ardelyx in a report on Tuesday, November 28th. Cantor Fitzgerald restated a buy rating and set a $12.00 price target on shares of Ardelyx in a report on Tuesday, November 21st. Ladenburg Thalmann Financial Services decreased their price target on shares of Ardelyx from $19.00 to $16.00 and set a buy rating for the company in a report on Wednesday, November 22nd. Finally, Citigroup upped their price target on shares of Ardelyx from $16.00 to $17.00 and gave the company a buy rating in a report on Wednesday, November 29th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $12.93.
Ardelyx (NASDAQ ARDX) traded down $0.05 during mid-day trading on Wednesday, reaching $5.75. 376,000 shares of the company’s stock were exchanged, compared to its average volume of 293,929. Ardelyx has a one year low of $4.05 and a one year high of $15.40. The company has a market capitalization of $275.70, a PE ratio of -2.58 and a beta of 0.44.
ILLEGAL ACTIVITY NOTICE: “Ardelyx (ARDX) Downgraded by BidaskClub to “Sell”” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.chaffeybreeze.com/2018/02/15/ardelyx-ardx-downgraded-by-bidaskclub-to-sell.html.
Ardelyx Company Profile
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.